AbClon, GC Biopharma partner on in vivo CAR-T using proprietary antibody
GC Biopharma and AbClon said Wednesday they would jointly develop a cancer therapy that reprograms T cells without removing them from a patient's body, entering a field that has drawn more than $7 billion in acquisitions from large pharmaceutical …